Showing results (11-20 of 131) with videos related to
Sort By:
Pageof 14
Pancreas|July 4, 2019
Impact of Changes in the American Joint Committee on Cancer Staging Manual, Eighth Edition, for Pancreatic Ductal AdenocarcinomaAri Kassardjian, Nicholas Stanzione, Timothy R Donahue, et al.The Oncologist|November 25, 2018
Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective AnalysisSamuel J Klempner, Steven B Maron, Leah Chase, et al.The Oncologist|March 2, 2017
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic AdenocarcinomaAl B Benson, Zev A Wainberg, J Randolph Hecht, et al.Nature Clinical Practice. Nephrology|January 26, 2007
Acute lymphoblastic leukemia presenting as acute renal failureWilliam M Suh, Zev A Wainberg, Sven de Vos, et al.Journal of the American College of Surgeons|April 11, 2017
Sex-Specific Differences in Colon Cancer when Quality Measures Are Adhered to: Results from International, Prospective, Multicenter Clinical TrialsShrawan G Gaitonde, Aviram Nissan, Mladjan Protić, et al.JAMA Ophthalmology|May 24, 2014
Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancerTara A McCannel, Bartosz Chmielowski, Richard S Finn, et al.Cancer Treatment Reviews|July 18, 2025
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinomaElizabeth C Smyth, Kyoung-Mee Kim, Sun Young Rha, et al.Frontiers in Oncology|August 29, 2024
Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging optionHaeseong Park, Samuel J Klempner, Joseph Chao, et al.Anti-Cancer Drugs|March 16, 2019
Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumorsJustin Hoffman, Jayeta Chakrabarti, Anna Plotka, et al.ESMO Open|May 17, 2018
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancerRichard M Goldberg, Clara Montagut, Zev A Wainberg, et al.Pageof 14